Pharmaceutical - Nephrology and Hepatology

Filter

Current filters:

Nephrology and Hepatology

Popular Filters

1 to 25 of 104 results

Advagraf plus basiliximab results in significantly better renal function

23-02-2015

Data published last week in the American Journal of Transplantation demonstrate that in liver transplant…

AdvagrafAstellas PharmaBasiliximabNephrology and HepatologyPharmaceuticalResearch

Astellas' once-daily Advagraf demonstrates superiority to twice-daily immediate release

Astellas' once-daily Advagraf demonstrates superiority to twice-daily immediate release

20-02-2015

Japanese drug major Astellas has published results of a study demonstrating that early and sustained…

AdvagrafAstellasNephrology and HepatologyPharmaceuticalResearch

NICE final draft guidance recommends Norgine's Targaxan

NICE final draft guidance recommends Norgine's Targaxan

19-02-2015

The UK’s National Institute for Health and Care Excellence has published its final draft guidance recommending…

Nephrology and HepatologyNeurologicalNorginePharmaceuticalRegulationTargaxanUK

AbbVie submits NDA to Japanese regulators for ombitasvir/ paritaprevir/ ritonavir combination in hepatitis C

AbbVie submits NDA to Japanese regulators for ombitasvir/ paritaprevir/ ritonavir combination in hepatitis C

12-02-2015

US drugmaker AbbVie has submitted a New Drug Application to the Japanese Ministry of Health, Labor and…

AbbVieJapanNephrology and Hepatologyombitasvir/paritaprevir/ritonavirPharmaceuticalRegulation

Indian company Zydus to present data on Lipaglyn in steatohepatitis

Indian company Zydus to present data on Lipaglyn in steatohepatitis

06-02-2015

Indian pharma company Zydus is to present data from its Lipaglyn (saroglitazar) study at the 2015 Keystone…

IndiaLipaglynNephrology and HepatologyPharmaceuticalResearchZydus Cadila

Long-term solutions needed for kidney disease, says EAF report

Long-term solutions needed for kidney disease, says EAF report

29-01-2015

Greater education and support for non-specialist health care professionals is needed to ensure the accurate…

EuropeHealthcareNephrology and HepatologyOtsuka PharmaceuticalPharmaceutical

Rockwell's Triferic cleared for marketing by US FDA

26-01-2015

The US Food and Drug Administration has approved US biopharma company Rockwell Medical’s Triferic (ferric…

Nephrology and HepatologyPharmaceuticalRegulationRockwell MedicalTrifericUSA

IQWiG reports negative views on Provenge, Velphoro and Zydelig

IQWiG reports negative views on Provenge, Velphoro and Zydelig

22-01-2015

The German Institute for Quality and Efficiency in Health Care (IQWiG) has reviewed a number of dossiers…

DendreonGermanyGilead SciencesNephrology and HepatologyOncologyPharmaceuticalPricingProvengeRegulationVelphoroVifor PharmaZydelig

Novo Nordisk's Victoza granted label extension in the UK

Novo Nordisk's Victoza granted label extension in the UK

20-01-2015

A license extension has been granted in the UK for Victoza (liraglutide) from Danish insulin giant Novo…

Nephrology and HepatologyNovo NordiskPharmaceuticalRegulationUKVictoza

Regado and Tobira to merge to create leading NASH company

Regado and Tobira to merge to create leading NASH company

14-01-2015

The USA’s Regado Biosciences and privately-held Tobira Therapeutics have entered into a definitive…

Mergers & AcquisitionsNephrology and HepatologyPharmaceuticalRegadoTobira TherapeuticsUSA

Debiopharm regains rights to alisporivir in hepatitis C from Novartis

Debiopharm regains rights to alisporivir in hepatitis C from Novartis

13-01-2015

Switzerland-based biopharma company Debiopharm has updated its arrangement with Novartis to regain full…

alisporivirDebiopharmLicensingNephrology and HepatologyNovartisPharmaceuticalResearch

CVS to cover Gilead’s hepatitis C drugs Harvoni and Sovaldi exclusively

CVS to cover Gilead’s hepatitis C drugs Harvoni and Sovaldi exclusively

06-01-2015

US pharmacy benefits manager CVS Health has entered into a deal with US biotech major Gilead Sciences…

GileadHarvoniNephrology and HepatologyPharmaceuticalPricingSovaldiUSA

Takeda ends partnership with AMAG Pharma on Rienso/Feraheme

Takeda ends partnership with AMAG Pharma on Rienso/Feraheme

30-12-2014

Japan’s largest drugmaker Takeda Pharmaceutical has entered into an agreement with US drugmaker AMAG…

AMAG PharmaceuticalsCanadaEuropeFerahemeHematologyLicensingNephrology and HepatologyPharmaceuticalRiensoTakeda Pharmaceutical

Achillion shares jump on positive interim results from ACH-3102 and ACH-322 for hepatitis C

Achillion shares jump on positive interim results from ACH-3102 and ACH-322 for hepatitis C

23-12-2014

US pharma company Achillion Pharmaceuticals saw its shares jump as much as 60% on the announcement of…

ACH-3102ACH-3422Achillion PharmaceuticalsNephrology and HepatologyPharmaceuticalResearchUSA

Sanofi accused of $34 million kickbacks by former paralegal employee

Sanofi accused of $34 million kickbacks by former paralegal employee

05-12-2014

Allegations have been made that French drug major Sanofi and members of its executive took part in a…

FranceLantusLegalNephrology and HepatologyPharmaceuticalSanofi

France negotiates lowest price in Europe for Gilead’s Sovaldi

France negotiates lowest price in Europe for Gilead’s Sovaldi

21-11-2014

The discount negotiated by the French government on hepatitis C drug Sovaldi (sofosbuvir), produced by…

FranceGilead SciencesNephrology and HepatologyPharmaceuticalPoliticsPricingRegulationSovaldi

Kissei files for Japanese approval of PA21 for hyperphosphatemia

21-11-2014

Japanese mid-sized drugmaker Kissei Pharmaceutical says that a new drug application for PA21 (development…

FreseniusJapanKissei PharmaceuticalNephrology and HepatologyPA21PharmaceuticalRegulationVelphoroVifor Pharma

Takeda joins forces with GE Healthcare on liver disease research

Takeda joins forces with GE Healthcare on liver disease research

13-11-2014

Japan’s largest drugmaker Takeda Pharmaceutical has entered into an alliance agreement with UK-based…

GE HealthcareJapanNephrology and HepatologyPharmaceuticalResearchTakeda Pharmaceutical

Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

12-11-2014

Pharma giant Merck & Co has presented results from its Phase II trial of grazoprevir/elbasvir, with or…

grazoprevir/elbasvirMerck & CoNephrology and HepatologyPharmaceuticalResearchUSA

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

Two Bristol-Myers Squibb drugs approved by Scottish Medicines Consortium

10-11-2014

The Scottish Medicines Consortium has approved two new treatments today, one for skin cancer and one…

Bristol-Myers SquibbDaklinzaNephrology and HepatologyOncologyPharmaceuticalRegulationUKYervoy

Islet Sciences announces merger with Brighthaven Ventures

Islet Sciences announces merger with Brighthaven Ventures

01-10-2014

Metabolic biopharma specialist Islet Sciences has announced a merger with Brighthaven Ventures, a privately-held…

Islet SciencesMergers & AcquisitionsNephrology and HepatologyPharmaceuticalremogliflozinUSA

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

29-09-2014

Achillion Pharmaceuticals is in a prime position to develop its own all-oral hepatitis C treatment as…

Achillion PharmaceuticalsFinancialMarkets & MarketingNephrology and HepatologyPharmaceuticalUSA

1 to 25 of 104 results

COMPANY SPOTLIGHT

Menarini

Back to top